Mark Kawakami - Arcadia Biosciences Chief Officer
| RKDA Stock | USD 2.74 0.15 5.79% |
Executive
Mark Kawakami is Chief Officer of Arcadia Biosciences
| Address | 5950 Sherry Lane, Dallas, TX, United States, 75225 |
| Phone | 214 974 8921 |
| Web | https://www.arcadiabio.com |
Latest Insider Transactions
Arcadia Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3872) % which means that it has lost $0.3872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5265) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.75. In addition to that, Return On Capital Employed is expected to decline to -0.91. At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 5.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Cole | Bridgford Foods | N/A | |
| Julie Roloson | Seneca Foods Corp | N/A | |
| Jennifer Condon | Better Choice | N/A | |
| John Exner | Seneca Foods Corp | 62 | |
| Kent Cunningham | Better Choice | 53 | |
| Amiee Castleberry | Seneca Foods Corp | N/A | |
| Zhimin Lu | Farmmi Inc | N/A | |
| Ryan Wilson | Better Choice | N/A | |
| Mary Sagona | Seneca Foods Corp | N/A | |
| Norma Garcia | Stryve Foods | N/A | |
| Michael Bridgford | Bridgford Foods | 42 | |
| Tim Blankenbaker | Better Choice | N/A | |
| Katie Grady | Stryve Foods | N/A | |
| Steven Richie | Laird Superfood | 55 | |
| Trevor Rousseau | Laird Superfood | N/A | |
Management Performance
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.39 |
Arcadia Biosciences Leadership Team
Elected by the shareholders, the Arcadia Biosciences' board of directors comprises two types of representatives: Arcadia Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arcadia. The board's role is to monitor Arcadia Biosciences' management team and ensure that shareholders' interests are well served. Arcadia Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arcadia Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Belinda Yao, VP Operations | ||
| Stanley Jacot, CEO President | ||
| Brian Schaffer, Senior Sales | ||
| Kevin Hodges, VP Operations | ||
| Thomas CFA, President CEO | ||
| Thomas Schaefer, CFO Secretary | ||
| Mark Kawakami, Chief Officer | ||
| Tracy Baker, Senior Operations | ||
| Pamela Haley, CFO Sec | ||
| Laura Pitlik, Chief Officer |
Arcadia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arcadia Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.15) % | ||||
| Current Valuation | (2.49 M) | ||||
| Shares Outstanding | 1.36 M | ||||
| Shares Owned By Insiders | 2.70 % | ||||
| Shares Owned By Institutions | 4.59 % | ||||
| Number Of Shares Shorted | 24.86 K | ||||
| Price To Earning | 4.84 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share 3.802 | Quarterly Revenue Growth (0.04) | Return On Assets (0.39) |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.